Who is eligible for clinical trial NCT07104383?

Participants must meet protocol criteria for Weight Loss. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT07104383 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-04-03

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) (NCT07104383)

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Viking Therapeutics, Inc.

🩺 Plain-English Summary (8th-Grade Level)

This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (3 items) and avoid the listed exclusions (13 items).

Location: Viking Clinical Site #2037 — Birmingham, Alabama

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Age ≥18 years of age at the time of signing the informed consent
Body mass index (BMI) ≥27 kg/m2
Have Type 2 Diabetes Mellitus according to the American Diabetes Association with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Type 2 diabetes mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation
Self-reported body weight change of 5% or more within 3 months of screening
Have a prior or planned surgical treatment for obesity (except for liposuction or abdominoplasty if performed \>1 year prior to screening)
Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)
Have Type 1 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 diabetes mellitus (T2DM)
Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening
Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG \< 54 mg/dL
Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values \> 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization
Have proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment
Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
History of acute or chronic pancreatitis

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (127 Sites)

Viking Clinical Site #2037 — Birmingham, Alabama
Viking Clinical Site #2064 — Birmingham, Alabama
Viking Clinical Site #2128 — Huntsville, Alabama
Viking Clinical Site #2005 — Chandler, Arizona
Viking Clinical Site #2017 — Flagstaff, Arizona
Viking Clinical Site #2018 — Peoria, Arizona
Viking Clinical Site #2135 — Scottsdale, Arizona
Viking Clinical Site #2019 — Tucson, Arizona
Viking Clinical Site #2036 — Little Rock, Arkansas
Viking Clinical Site #2071 — Chula Vista, California
Viking Clinical Site #2070 — Escondido, California
Viking Clinical Site #2054 — Huntington Park, California
Viking Clinical Site #2014 — Lake Forest, California
Viking Clinical Site #2129 — Lemon Grove, California
Viking Clinical Site #2051 — Lincoln, California
Viking Clinical Site #2050 — Long Beach, California
Viking Clinical Site #2078 — Manteca, California
Viking Clinical Site #2053 — Montclair, California
Viking Clinical Site #2068 — Panorama City, California
Viking Clinical Site #2132 — Rolling Hills Estates, California
Viking Clinical Site #2131 — San Diego, California
Viking Clinical Site #2052 — Spring Valley, California
Viking Clinical Site #2109 — Tustin, California
Viking Clinical Site #2067 — Van Nuys, California
Viking Clinical Site #2079 — Walnut Creek, California

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗